Skip to the beginning of the images gallery

LY2157299 - ≥99%, high purity , TGF-beta receptor type I inhibitor, CAS No.700874-72-2, TGF-beta receptor type I inhibitor

Specifications & Purity: ≥99%

CAS#: 700874-72-2
Formula: C₂₂H₁₉N₅O
Molecular Weight: 369.42
PubChem CID: 10090485

Item Number

L126937

Grouped product items
SKU	Size	Availability	Price
L126937-5mg	5mg	Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!	$48.90
L126937-10mg	10mg	Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!	$68.90
L126937-50mg	50mg	Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!	$147.90

Highly potent TGF-beta kinase antagonist

View related series

activin A receptor type 1B Inhibitor bone morphogenetic protein receptor type IB Inhibitor transforming growth factor beta receptor 1 Inhibitor transforming growth factor beta receptor 2 Inhibitor

Basic Description

Synonyms	Galunisertib\|700874-72-2\|LY2157299\|LY 2157299\|LY-2157299\|4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide\|ly2157299(galunisertib)\|UNII-3OKH1W5LZE\|Galunisertib (LY2157299)\|Galunisertib [USAN]\|3OKH1W5LZE\|4-[2-(6-
Specifications & Purity	≥99%
Storage Temp	Store at -20°C
Shipped In	Dry ice
Action Type	INHIBITOR
Mechanism of action	TGF-beta receptor type I inhibitor

Associated Targets

TGFBR1 Tchem TGF-beta receptor type-1 3 Activities

Discover Target: TGFBR1

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

TGFBR2 Tchem TGF-beta receptor type-2 1 Activities

Discover Target: TGFBR2

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

RIPK3 Tchem Receptor-interacting serine/threonine-protein kinase 3 1 Activities

Discover Target: RIPK3

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

MINK1 Tchem Misshapen-like kinase 1 1 Activities

Discover Target: MINK1

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

BMPR1B Tchem Bone morphogenetic protein receptor type-1B 1 Activities

Discover Target: BMPR1B

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

ACVR1B Tchem Activin receptor type-1B 2 Activities

Discover Target: ACVR1B

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Names and Identifiers

IUPAC Name	4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide
INCHI	InChI=1S/C22H19N5O/c1-13-4-2-5-18(25-13)21-20(19-6-3-11-27(19)26-21)15-9-10-24-17-8-7-14(22(23)28)12-16(15)17/h2,4-5,7-10,12H,3,6,11H2,1H3,(H2,23,28)
InChi Key	IVRXNBXKWIJUQB-UHFFFAOYSA-N
Canonical SMILES	CC1=NC(=CC=C1)C2=NN3CCCC3=C2C4=C5C=C(C=CC5=NC=C4)C(=O)N
Isomeric SMILES	CC1=NC(=CC=C1)C2=NN3CCCC3=C2C4=C5C=C(C=CC5=NC=C4)C(=O)N
PubChem CID	10090485
Molecular Weight	369.42

PubChem CID

10090485

ChEMBL Ligand

CHEMBL2364611

CAS Registry No.

700874-72-2

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

1 results found

Lot Number	Certificate Type	Date	Item
J1521097	Certificate of Analysis	May 10, 2023	L126937

References

1. Li HY, McMillen WT, Heap CR, McCann DJ, Yan L, Campbell RM, Mundla SR, King CH, Dierks EA, Anderson BD et al.. (2008) Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent.. J Med Chem, 51 (7): (2302-6). [PMID:18314943]
2. Yingling JM, McMillen WT, Yan L, Huang H, Sawyer JS, Graff J, Clawson DK, Britt KS, Anderson BD, Beight DW et al.. (2018) Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor.. Oncotarget, 9 (6): (6659-6677). [PMID:29467918]

Solution Calculators

Molarity Calculator

Determine the necessary mass, volume, or concentration for preparing a solution.

Dilution Calculator

Determine the dilution needed to prepare a stock solution.